Biocon Share price

Q: How to buy Biocon Share at Choice?

To buy Biocon stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

BIOCON

Healthcare Large Cap

416.8

8.85 (-2.08%)

NSE

BSE

Last updated on 2 Jun, 2026 | 15:42 IST

BUYSELL

Today's High

426.25

Today's Low

410.35

52 Week Low

327.60

52 Week High

440.40

Free Demat with Zero AMC*

Biocon Chart

ChartIQ

TradingView

Biocon Share Key Metrics

Volume

30.31 L

Market Cap

67559.44 CR

LTQ@LTP

5@416.80

ATP

417.49 Var Margin

15.32 %

Circuit Range

383.1-468.2

Delivery %

56.19 %

Value

126.53 CR

ASM/GSM

No

Market Lot

1

Summary

Biocon share price is ₹416.8 as of 2 Jun, 2026. The stock Biocon intraday movement has stayed between ₹410.35 and ₹426.25, while on a 52-week basis,Biocon price 52 week high is ₹440.40 & its 52 week low is ₹327.60.

In terms of trading activity, Biocon has recorded a volume of 3030795 shares, The Biocon has a market cap of ₹1620907773 CR. The stock’s Average Traded Price (ATP) stands at ₹417.49, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5 @ ₹416.80.

Biocon operates within a circuit range of ₹383.10 – ₹468.20, with a Value of ₹126.53 CR. The Delivery Percentage for the day is 56.19%. Additionally, Biocon currently falls under the No framework, and trades with a market lot size of 1.

Biocon Fundamentals

P/E Ratio

178.86

P/B Ratio

2.03

Div. Yield

0.12

Sector P/E

69.94

Sector P/B

2.97

Sec. Div. Yield

0.55

Biocon Resistance and Support

Pivot 428.38

Resistance

First Resistance

432.26

Second Resistance

438.88

Third Resistance

442.76

Support

First Support

421.76

Second Support

417.88

Third Support

411.26

Biocon Futures & Options

Biocon Ltd Share Price

416.8 -8.85 (-2.08%)

Biocon Option Chain

View Price, OI, Greeks & More...

View All

30JUN26

421.05 -8.15 (1.90%)

28JUL26

421.90 -8.80 (2.04%)

25AUG26

426.60 -8.00 (1.84%)

BIOCON|30JUN26 CE 415.00

16.30 -5.3 (-24.54%)

BIOCON|30JUN26 PE 420.00

12.3 3.3 (36.67%)

Biocon Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

44.91%

Mutual Fund

16.53%

Insurance

6.16%

Foreign Institutional Investors

7.52%

Domestic Institutional Investors

1.38%

Retail

23.49%

Others

0.01%

Total Promoters

MAR '26

44.91%

Biocon Corporate Actions

Date	Agenda
2026-05-07	Audited Results & Final Dividend
2026-02-12	Quarterly Results
2025-11-11	Quarterly Results
2025-10-01	Redemption (Part) of NCD
2025-08-07	Quarterly Results
2025-05-08	Audited Results & Final Dividend
2025-04-23	Others
2025-04-04	To consider Fund Raising
2025-01-30	Quarterly Results & Others
2025-01-27	Others

Biocon News

Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Biocon issued a corrigendum to its postal ballot, updating terms for a preferential issue. The issue price is now ₹376.41 per share, and the swap ratio is 0.76159 equity shares for every 100 Biocon Biologics shares, aiming for full ownership of BBL.

May 29 2026 21:16:21

Biocon Limited

Biocon released the transcript of its Q4 FY26 earnings call, detailing a strong year-end performance, successful integration of biosimilar and generic businesses, and significant debt reduction. Management provided a positive outlook on new product launches and increased operating leverage, particularly in H2 FY27.

May 14 2026 16:29:51

Biocon shares gain after Health Canada approval for injection used in treating bloodstream infections

Biocon Pharma Limited, a subsidiary of Biocon, has received approval from Health Canada for its Micafungin for Injection, USP (50 mg and 100 mg). This antifungal medication is indicated for treating various fungal infections in adults and pediatric patients, and for prophylaxis in hematopoietic stem cell transplant patients. This regulatory clearance is expected to enhance Biocon's integrated biosimilars and generics portfolio and expand its presence in the Canadian market.

May 11 2026 10:28:04

Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion

Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, has named her niece Claire Mazumdar as her successor, outlining a five-year transition plan. The company also announced plans to target peak revenue of $500 million to $700 million from Semaglutide by FY30, with a push starting from FY28, and aims to reduce its current debt of $1.8 billion to $1.1 billion by FY28.

May 11 2026 09:00:00

Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Biocon has initiated a Postal Ballot for shareholder approval on several key resolutions. These include revisions to Executive Chairperson's remuneration, the appointment of Shreehas Pradeep Tambe as CEO & MD, and a preferential issue of equity shares to acquire the remaining minority stake in Biocon Biologics, making it a wholly-owned subsidiary for strategic integration.

May 09 2026 01:28:54

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Biocon announced the availability of the audio and video recording of its Q4 FY26 Earnings Call, held on May 08, 2026. Investors can access the recording via links provided on the company's website.

May 08 2026 21:31:21

Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore

Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.

May 08 2026 10:05:10

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.

May 08 2026 00:04:07

Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.

May 07 2026 23:46:24

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities

Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.

May 07 2026 23:44:26

Name	Position
Kiran Mazumdar-Shaw	Chairperson
Ravi Rasendra Mazumdar	Non Independent & Non Executive Director

Biocon Similar Stocks

Max Healthcare Institute Ltd.

948.70

10.25 (1.09%)

Lenskart Solutions Ltd.

524.20

5.25 (1.01%)

Aurobindo Pharma Ltd.

1429.20

-4.50 (0.31%)

Laurus Labs Ltd.

1382.60

-5.80 (0.42%)

Fortis Healthcare Ltd.

929.40

0.20 (0.02%)

Alkem Laboratories Ltd.

5239.00

-75.50 (1.42%)

Glenmark Pharmaceuticals Ltd.

2184.60

-16.60 (0.75%)

Abbott India Ltd.

26295.00

-545.00 (2.03%)

Anthem Biosciences Ltd.

755.60

1.55 (0.21%)

Narayana Hrudayalaya Ltd.

1934.20

29.70 (1.56%)

Biocon FAQs

The Buying Price of Biocon share is 416.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Biocon stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Biocon shares is 178.86. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Biocon shares is 2.03. Useful to assess the stock's value relative to its book value.

To assess Biocon’s valuation compare Sector P/E, P/B which are 69.94 & 2.97 with sector averages, along with growth rates and financial metrics.

The Market Cap of Biocon is 67559.44 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Biocon share price is 440.40 & 327.60. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Biocon belongs to the Healthcare sector.